Full text is available at the source.
Tirzepatide as a new heart-protecting treatment for type 2 diabetes and obesity
Updated
Abstract
Tirzepatide significantly decreased blood pressure, body weight, and HbA1c in the SURPASS-4 trial.
- Obesity and diabetes mellitus are important risk factors for cardiovascular disease.
- Tirzepatide, a dual receptor agonist, has shown cardioprotective effects.
- The SURMOUNT-1 trial indicated that tirzepatide effectively reduces cardiometabolic risk factors in individuals with obesity without diabetes.
- Improvements in lipid profiles and increased insulin secretion are associated with tirzepatide treatment.
- Tirzepatide may reduce inflammation and promote endothelial integrity, which are beneficial for cardiovascular health.
- Current evidence suggests that tirzepatide could impact cardiovascular health beyond its antidiabetic effects.
Simplified